Application 205055
- Type
- ANDA
- Sponsor
- ALVOGEN
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | NATEGLINIDE | NATEGLINIDE | TABLET;ORAL | 60MG | No | No |
| 002 | NATEGLINIDE | NATEGLINIDE | TABLET;ORAL | 120MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A205055-001 | NATEGLINIDE | NATEGLINIDE | 60MG | TABLET / ORAL | 2015-12-11 | ||
| A205055-002 | NATEGLINIDE | NATEGLINIDE | 120MG | TABLET / ORAL | 2015-12-11 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-10-28 04:53 UTC | 2022-10 | A205055-001 | NATEGLINIDE | 60MG | TABLET / ORAL | 2015-12-11 | f41ea6bd6efb… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A205055-002 | NATEGLINIDE | 120MG | TABLET / ORAL | 2015-12-11 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A205055-001 | NATEGLINIDE | 60MG | TABLET / ORAL | 2015-12-11 | e64feba35796… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A205055-002 | NATEGLINIDE | 120MG | TABLET / ORAL | 2015-12-11 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A205055-001 | NATEGLINIDE | 60MG | TABLET / ORAL | 2015-12-11 | cb3db0bc1861… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A205055-002 | NATEGLINIDE | 120MG | TABLET / ORAL | 2015-12-11 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A205055-001 | NATEGLINIDE | 60MG | TABLET / ORAL | 2015-12-11 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A205055-002 | NATEGLINIDE | 120MG | TABLET / ORAL | 2015-12-11 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | A205055-001 | AB | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | A205055-002 | AB | 1 | 74a2ff9319b5… |
| 2019-12-14 00:12 UTC | 2019-12 | A205055-001 | AB | 1 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | A205055-002 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A205055-001 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | A205055-002 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A205055-001 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | A205055-002 | AB | 1 | ea99ee380514… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nateglinide | NATEGLINIDE | Golden State Medical Supply, Inc. | e920b343-f53e-7487-e053-2995a90a719a | 2025-04-15 | Warnings, Adverse reactions | Nateglinide NATEGLINIDE |
| Nateglinide | NATEGLINIDE | Strides Pharma Science Limited | 0ccf9b07-3c21-482d-abeb-a06ceb482c7b | 2025-02-24 | Warnings, Adverse reactions | Nateglinide NATEGLINIDE |
| Nateglinide | NATEGLINIDE | American Health Packaging | b17ead66-dc11-4e54-9ba6-00619510f27b | 2025-01-07 | Warnings, Adverse reactions | Nateglinide NATEGLINIDE |
| Nateglinide | NATEGLINIDE | Zydus Lifesciences Limited | a82817dd-f8c4-4172-ba86-63c2beef456a | 2024-12-03 | Nateglinide NATEGLINIDE | |
| NATEGLINIDE | NATEGLINIDE | Rising Pharma Holdings, Inc. | b41f4180-96a7-411d-b827-5021e534f556 | 2024-12-03 | Warnings, Adverse reactions | NATEGLINIDE NATEGLINIDE |
| Nateglinide | NATEGLINIDE | Zydus Pharmaceuticals USA Inc. | 88698921-cd8f-4d41-96e6-ff671913c5c3 | 2023-11-07 | Warnings, Adverse reactions | Nateglinide NATEGLINIDE |
| Nateglinide | NATEGLINIDE | Cadila Pharmaceuticals Limited | c678b772-acba-4b59-a0b2-d70d84283425 | 2022-12-28 | Warnings, Adverse reactions | Nateglinide NATEGLINIDE |
| Nateglinide | NATEGLINIDE | Dr. Reddy's Laboratories Limited | f7b28951-76d2-cabd-64a1-b74aa225c6e9 | 2021-11-27 | Warnings, Adverse reactions | Nateglinide NATEGLINIDE |
| Nateglinide | NATEGLINIDE | Modavar Pharmaceuticals LLC | af81465b-5f49-4eeb-8122-ef7fe5d90ddc | 2021-08-03 | Warnings, Adverse reactions | Nateglinide NATEGLINIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 32623 | ORIG | 2015-12-16 |